钠葡萄糖协同转运子2抑制剂：糖尿病治疗的新选择  

Sodium glucose co-transporter 2 inhibitors：A novel option for the treatment of diabetes

作　　者：袁璐[1] 李倩[1] 高谷[1] 马建华[1] 

机构地区：[1]南京医科大学附属南京第一医院内分泌科,210006

出　　处：《国际内分泌代谢杂志》2010年第5期321-323,共3页International Journal of Endocrinology and Metabolism

摘　　要：钠葡萄糖协同转运子2（SGLT2）是几乎仅在近曲小管表达的跨膜蛋白，介导了90％滤过葡萄糖的重吸收，SGLT2抑制剂可特异性抑制肾小管对滤过葡萄糖的重吸收，增加尿糖排泄，发挥降糖作用。SGLT2抑制剂还具有促进体重下降，间接改善肥胖的作用。根皮苷作为人类最早发现的SGLT2抑制剂，研究较为局限，随着T-1095、serglilozin、dapagliflozin等新型SGLT2抑制剂的开发，SGI胞抑制剂在治疗糖尿病上的有效性和安全性得到了进一步论证，为糖尿病治疗提供了新选择。The sodium glucose co-transporter 2 （SGLT2） located in the plasma membrane of cells lining the proximal tubule mediates 90 percent of renal glucose reabsorption from the tubular fluid. Competitive inhibitors of SGLT2 that provoke the renal excretion of glucose have been discovered,which can lower the elevated blood glucose levels in patients with diabetes. The SGLT2 inhibitors also play roles in weight loss, which can improve the obesity. As the earliest SGLT2 inhibitor, the research of phlorizin are limited. With the development of novel SGLT2 inhibitors,such as T-1095, serglilozin and dapagliflozin, the efficacy and safety of SGLT2 inhibitors in the terms of treating diabetes has been fnrther confirmed, so the SGLT2 inhibitors provide new approaches to the treatment of diabetes mellitus.

关 键 词：钠葡萄糖协同转运子2抑制剂 SGLT2抑制剂 糖尿病 治疗 

分 类 号：R587.1[医药卫生—内分泌]